Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7306 to 7320 of 8202 results

  1. Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940

    Discontinued [GID-TA10397]

    Technology appraisal guidance
    Discontinued

  2. Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

    Discontinued [GID-TA10686]

    Technology appraisal guidance
    Discontinued

  3. Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]

    Discontinued [GID-TA10687]

    Technology appraisal guidance
    Discontinued

  4. Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

    Discontinued [GID-TA10447]

    Technology appraisal guidance
    Discontinued

  5. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

    Discontinued [GID-TA10144]

    Technology appraisal guidance
    Discontinued

  6. Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]

    Discontinued [GID-TA10688]

    Technology appraisal guidance
    Discontinued

  7. Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]

    Discontinued [GID-TA10709]

    Technology appraisal guidance
    Discontinued

  8. AT406 for neoadjuvant treatment of epithelial ovarian cancer [ID1428]

    Discontinued [GID-TA10809]

    Technology appraisal guidance
    Discontinued

  9. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

    Discontinued [GID-TA10569]

    Technology appraisal guidance
    Discontinued

  10. Pembrolizumab for previously treated endometrial cancer [ID1205]

    Discontinued [GID-TA10243]

    Technology appraisal guidance
    Discontinued

  11. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development [GID-TA10900] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Diabetes - buccal insulin [ID311]

    Discontinued [GID-TAG244]

    Technology appraisal guidance
    Discontinued

  13. Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

    Discontinued [GID-TAG496]

    Technology appraisal guidance
    Discontinued

  14. Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

    Discontinued [GID-TAG494]

    Technology appraisal guidance
    Discontinued

  15. ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

    Discontinued [GID-TA10445]

    Technology appraisal guidance
    Discontinued